Background. This study investigated gp120-binding antibody and neutralizing activity, at the gingival-and cervical-mucosal levels, in response to a bivalent gp120 candidate vaccine.
World wide, ϳ4.1 million individuals became infected with HIV during 2005, an incidence that has remained relatively unchanged since the mid-1990s despite a continued escalation of HIV-prevention efforts [1] . One of the best potential means to decrease HIV-1 incidence globally would be the development of a safe and effective preventive HIV vaccine that exhibits broadly neutralizing antibodies. Recent evidence suggesting that humoral immunity, especially at the mucosal level, may play a major role in preventing HIV infection supports this approach [2] . Local mucosal antibody controls HIV replication within local tissues before systemic dissemination and may be more effective than a systemic immune response [3, 4] . A few animal studies have demonstrated protection at the mucosal level after administration of parenteral live or recombinant candidate HIV vaccine [5] [6] [7] .
Numerous animal studies have demonstrated the presence of neutralizing antibodies [8, 9] and HIV-1-specific antibodies [10 -14] in intestinal, bronchial, nasal, and vaginal secretions after vaccine administration, regardless of the type of vaccine. Human studies have examined the effect of mucosal immunization and the ability to induce cholera toxin B subunit-specific IgA antibodies [15, 16] . However, no studies have examined the mucosal antibody response after administration of parenteral HIV vaccine in humans, and no studies have examined this in the context of other important causes of inflammation, such as concurrent sexually transmit-ted disease (STD), bacterial vaginosis (BV), cervicovaginal leukocytes, and the presence of cervicovaginal semen. Studies of cervicovaginal antibodies to HIV-1 and of cervicovaginal neutralizing activity in highly HIV-exposed but -uninfected (EU) women [17] [18] [19] [20] [21] may also make important contributions to the development of an HIV vaccine active at the mucosal level.
During 1998 -2002, VAX004 (VaxGen), a multicenter phase 3 trial of HIV-vaccine efficacy, studied 5417 participants in North America and the Netherlands to evaluate the efficacy that a recombinant bivalent gp120 subtype B vaccine (AIDSVAX B/B; VaxGen) has in preventing sexual transmission of HIV-1 [22] . Results from VAX004 demonstrate that the vaccine is not effective in preventing HIV infection, despite earlier evidence of both the induction of neutralizing antibodies in vaccine recipients [23] and an increase of binding antibodies in plasma 2 weeks after vaccination [24] . However, with an HIV seroincidence of 3.28/100 person-years, the female participants in VAX004 who were enrolled at 1 site (the University of Illinois at Chicago) constituted one of the highest-risk groups in the United States and presented a valuable opportunity for evaluation of mucosal response to vaccine administration. In the following analysis, we examine, in a cohort of EU female participants, the vaccine's effects on both binding antibody at the gingival-and cervicovaginal-mucosal levels and potential neutralizing activity at the cervicovaginal level.
SUBJECTS, MATERIALS, AND METHODS
Participants and specimen collection. Methods for participant recruitment and the study design of VAX004 have been published elsewhere [22] . At enrollment, all female participants in VAX004 (n ϭ 105) were HIV seronegative and reported no current injection drug use. They reported either at least 1 HIVseropositive male sex partner or at least 2 of the following risk factors during the preceding 6 months: crack cocaine use; exchange of sex for money, drugs, or shelter; at least 5 male sex partners; or a history of STD during the preceding year. Trial participants received 7 immunizations during a 36-month study period. Blood specimens were collected immediately before and 2 weeks after each immunization [24] .
Recruited for participation in an additional, mucosalimmunity substudy were 37 Chicago female participants. During a 36-month study period, they received 7 immunizations (at 0, 1, 6, 12, 18, 24, and 30 months). Gingival and cervicovaginallavage (CVL) specimens were collected from the 37 participants 2 weeks after immunization, during clinic visits to evaluate immunogenicity, when immune responses are considered to be maximum; no specimens were collected during the immunization visits. Gingival specimens were collected by use of the Orasure oral collection device and were processed within 2 h. For all substudy participants, a pelvic examination was performed, and vaginal secretions were collected from the posterior fornix by use of a swab, for preparation of a wet-mount slide. Subsequently, CVL specimens were collected by directing a 10-mL stream of sterile normal saline at the cervical os and the endocervix. Fluid pooled in the posterior fornix of the vagina was aspirated and centrifuged to pellet cells and was processed within 2 h. Wetmount slides were prepared in saline for the diagnosis of T. vaginalis. The CVL specimens were tested for the presence of blood (ChemStrip analysis; Roche Diagnostics) and seminal p30 (Abacus Diagnostics) and then were centrifuged at 600 g for 15 min; the resulting supernatant was frozen at Ϫ70°C. All cervicovaginal specimens (i.e., swabs and CVL) were screened for Chlamydia trachomatis and Neisseria gonorrhoeae (Gen-Probe and Becton Dickinson), and the presence of BV was determined by use of the Amsel criteria [25] . Incident cases of STD and BV were treated. The protocol was approved by the local and Centers for Disease Control and Prevention institutional review boards, and written informed consent was obtained in accordance with the institutional review boards' policies.
Vaccine and placebo. The study vaccine contained 2 recombinant gp120 (rgp120) HIV-1 envelope antigens (300 mg each of MN rgp120 and GNE8 rgp120 [AIDSVAX B/B]) that had been derived from 2 different subtype B strains and that were adsorbed onto 600 mg of alum [26] . GNE8 gp120 was cloned directly from peripheral-blood mononuclear cells (PBMCs) and had the CCR5 phenotype; the GNE8 gp120 DNA sequence has been deposited into the GenBank database (accession no. AY771703). Placebo consisted of alum only.
Binding-antibody assay. All plasma, gingival, and CVL specimens were tested for the HIV antibodies, gp120-specific IgG or IgA, by ELISA. In brief, wells of microtiter plates were coated with MN rgp120 (1 g/mL) and were blocked with mild buffer (5% nonfat dry-milk powder, 0.3% Tween 20 in 0.01 PBS at mol/L [pH 7.4]). For detection of IgA, competing IgG from a serum or mucosal specimen was removed by adsorption with protein-G Sepharose. Diluted serum (1:100) or mucosal specimen (1:1) in milk buffer was incubated to allow binding of specific IgG or IgA. Bound antibodies were then detected by incubation with a IgG-specific (␥ chain) peroxidase conjugate (goat anti-human IgG peroxidase) or IgA-specific (␣ chain) peroxidase conjugate (goat anti-human IgA peroxidase). Qualitative ELISA was performed to detect gp120-specific IgG or IgA, and data were analyzed in a semiquantitative manner that, for comparative purposes, considered the optical-density value. Absorbance values were considered to be positive if they were 3 SDs greater than the mean value in low-risk controls.
Viral isolates. HIV-1 MN was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (HIV-1 BaL and HIV-1 MN [originally designated "HTLV-III MN /H9"] were obtained from Dr. Robert Gallo) [27, 28] . HIV-1 BaL was propagated in phytohemagglutinin-stimu-lated normal donor PBMCs (5 mg/mL) (Sigma), and HIV-1 MN was propagated in CEM-SS cells.
The primary isolate HIV-1 01USUIC01 was obtained from a woman acutely infected via sexual exposure. PBMCs were isolated from her and were cocultured with phytohemagglutininstimulated normal donor PBMCs.
Neutralizing-activity assay. Potential neutralizing activity against either HIV-1 MN or HIV-1 01USUIC01 was measured in cervicovaginal specimens by use of the TZM-bl reporter cell line, obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (TZM-bl was obtained from Dr. John C. Kappes, Dr. Ziaoyun Wu, and Tranzyme [29 -31] ). The TZM-bl reporter cell line has an HIVlong terminal repeat-luciferase construct and expresses CD4 and CCR5. Freshly trypsinized cells (50,000 cells/well) in CRPMI were plated onto a 48-well plate and were incubated overnight at 37°C. The next day, heat-inactivated CVL specimens were serially diluted, in 2-fold increments, with RPMI supplemented with 10% fetal calf serum (CRPMI), generating of 1:4, 1:8, 1:16, and 1:32. HIV-1 MN stock (3,000 pg of p24 antigen/ mL) was added to CVL specimens in a 1:1 (vol/vol) ratio. The CVL-HIV-1 MN mix was incubated for 1 h at 37°C and then was added to TZM-bl cells in a 48-well plate with diethylaminoethyl (DEAE), at a final concentration of 10 g/mL. The plate was incubated for 2 h at 37°C. After incubation for 2 h, 700 L of CRPMI with 10 g/mL DEAE was added to each well. Incubation was continued for 48 h at 37°C. After The TZM-bl cells were then washed 3 times with 1ϫ PBS, and lysis of the cells was performed with 1ϫ lysis buffer. After 200 L of 1ϫ lysis buffer was added, the luciferase assay was performed on the cell lysate by use of a luciferase kit (Promega). TZM-bl cells suspended in CRPMI and 10 g/mL DEAE only and TZM-bl cells treated with HIV-1 MN or HIV-1 01USUIC01 in the absence of CVL were used as negative and positive controls, respectively. All experiments were performed in triplicate. Neutralization activity was defined as Ͼ50% inhibition of luciferase activity at the lowest dilution and as a dose/response effect observed in serial dilutions for HIV-1 MN . The use of indinavir during the incubation period had no effect on the sensitivity of the assay and therefore was not used.
Statistical analysis. To avoid bias, specimen collection and assay analyses were conducted blinded to the participant's vaccine status. Statistical analysis was performed by use of the SAS/ STAT software. Summary statistics for cohort sociodemographics, HIV risk factors, and cervicovaginal-specimen characteristics such as the presence of leukocytes, cervicovaginal semen, and STD were obtained. Collected cervicovaginal, gingival, and plasma specimens represented the unit of analysis. Associations between dependent variables (binding antibodies and neutralizing activity) and independent variables (vaccine status) were first examined individually by use of the 2 statistic and Fisher's exact test. The power to detect differences between the vaccine recipients and the placebo recipients may have been increased by the use of linear regression analyses with absorbance values of antibodies used as the continuous dependant variable. However, the interpretation of absorbance values is difficult, especially in measurements of IgA, for which the relative values may be different between groups yet not achieve a meaningful "positive" cutoff value or threshold. Therefore, multivariate logistic regression models were used to examine the same relationship, with adjustment for potential confounders (STD, cervicovaginal semen, cervicovaginal leukocytes, and number of sexual partners) that, in exact conditional logistic regression analyses, demonstrated a statistically significant relationship (P р .20) with the dichotomous dependent variable (binding antibodies and neutralizing antibodies). Generalized estimating equations were used in the final models, to account for repeated measures of specimens from participants. In all models, variables were considered to be statistically significant at the P р .05 level.
RESULTS
The 37 high-risk HIV-uninfected Chicago participants enrolled in the substudy and included in this analysis made 201 study visits, during which 344 specimens-94 plasma, 158 cervicovaginal, and 92 gingival-were collected. All of these participants were African American. At all study visits, baseline sociodemographics, HIV risk factors, and clinical characteristics measuring cervical inflammation were not different between the group vaccine and the placebo recipients ( Binding anti-gp120 antibodies were found in all 3 compartments examined-cervicovaginal, gingival, and plasma. In bivariate analyses, vaccine recipients were more likely than placebo recipients to have IgG binding antibodies in all 3 compartments tested and to have only IgA binding antibody in plasma (P Ͻ .0001). The number of cervical and gingival specimens with IgA binding antibody specimens was limited, and the presence of cervicovaginal IgA did not differ between the vaccine recipients and the placebo recipients (OR, 0.63 [P ϭ .72]). The cervicovaginal IgG response was dramatically increased after 6 months (3 vaccinations) and remained high throughout the course of immunizations.
In multivariate analyses controlling for potential confounders, the relationship between immunization and binding antibodies was maintained. However, the strength of the relationship between vaccine and cervicovaginal IgG was weakened by the presence of cervicovaginal leukocytes (table 2) . Additional logistic regression modeling using interaction terms demonstrated that the term "immunization/presence of cervicovaginal leukocytes" independently predicted the presence of cervicovaginal IgG (but not cervicovaginal IgA) after the analysis was controlled for study visit, number of specimens, the presence of trichomonas, and the presence of cervicovaginal semen (OR, 15.9 [P ϭ .04]). The additional interaction terms "immunization/BV" and "immunization/trichomonas" did not predict the presence of cervicovaginal IgG or IgA.
A comparison of antibodies in different mucosal compartments demonstrated that the presence of cervicovaginal IgG and gingival IgG were highly correlated (OR, 36.6 [P Ͻ .0001]) in vaccine recipients. However, there was no correlation between IgG binding antibodies, STD, BV, cervicovaginal semen, or cervicovaginal leukocytes (table 3) . Cervicovaginal IgA was distinctly absent from most specimens and was found in only 3 (1.9%) of 156 specimens, which limited the use of this variable in analyses. Plasma IgA was highly correlated with cervicovaginal IgG (OR, 14.9 [P Ͻ .0001]) and gingival IgG (OR, 17.4 [P Ͻ .001]).
Cervicovaginal neutralizing activity against HIV-1 MN was present in 2 (16.7%) of the 12 participants tested at baseline (i.e., the first study visit). At baseline, cervicovaginal IgG and IgA binding antibodies were found in 1 (12.5%) of 8 and 0 (0%) of 8 participants, respectively. In all specimens from vaccine recipients and placebo recipients that were examined (n ϭ 41), cervicovaginal neutralizing activity was positively associated with the presence of cervicovaginal semen (OR, 13.3 [P ϭ .05]) (table 3) . There was no relationship between immunization and neutralizing activity, in either bivariate or multivariate modeling (table  2) . Furthermore, logistic regression modeling demonstrated that, within the same cervicovaginal specimens from the vaccine recipients, neutralizing activity was not associated with cervicovaginal HIV-specific IgG or IgA binding antibodies (OR, 6.0 [P ϭ .29]) after the analysis was controlled for study visit, number of specimens, and the presence of cervicovaginal semen. When the regression models in table 2 were remodeled to exclude cervicovaginal specimens with cervicovaginal semen, the statistical significance of our final results did not change (data not shown).
Cervicovaginal neutralizing activity against HIV-1 01USUIC01 was detected in 18.9% (7/36) of participants and in 7.9% (11/ 140) of specimens. Cervicovaginal neutralizing activity against HIV-1 01USUIC01 was not significantly associated with either immunization, binding antibody in all 3 compartments, cervicovaginal semen, STD, or cervicovaginal neutralizing activity against HIV-1 MN (data not shown).
DISCUSSION
The present study is the first to examine the presence of mucosal binding antibodies and neutralizing activity in female participants in a trial of HIV-vaccine efficacy. Specimens from recipients of gp120 vaccine provided robust binding-IgG responses in all compartments (plasma, cervicovaginal, and gingival) examined; however, vaccination was associated with the presence of IgA in only 1 compartment: plasma. Furthermore, immunization was not associated with anti-HIV cervicovaginal neutralizing activity, and cervicovaginal inflammation (measured on the basis of cervicovaginal leukocytes and other STDs) may complicate analyses of local vaccine effect, possibly by increasing transudation from the plasma compartment.
IgG antibodies were found in all 3 compartments. The levels of cervicovaginal and gingival IgG suggested that there was transudation across the mucosa, and they were strongly associated with the presence of plasma IgG and IgA. Although vaccine recipients had high levels of plasma IgA, cervicovaginal and gingival IgA were found in only 1.9% of cervicovaginal specimens and 8.2% of gingival specimens, in both the vaccine recipients and 
NOTE.
Comparisons of the 2 groups of recipients were determined by 2 statistic (for categorical variables) and 2-sided t test (for continuous variables); differences between the 2 groups of recipients were not statistically significant.
a All participants were self-identified as African American. b All of participants' study visits (n ϭ 201) were taken into account.
the placebo recipients. The contrast between the presence of cervicovaginal IgG and the absence of IgA would seem to indicate that IgA does not transudate into mucosal sites after parenteral vaccination and is consistent with secretory, and not passive, transudation of IgA across mucosal membranes [32] . Anti-gp41 IgA may serve as an important mediator of HIV infection, as has recently been described in Cambodia [2] , although cervicovaginal specimens were not examined in that study. The findings of the present study emphasize the need to examine the mucosal compartment, because the presence of a high level of plasma IgA may not be associated with the presence of other mucosal antibodies of the IgA type. The close association between cervicovaginal and gingival IgG antibody responses, as well as their correlation with immunization, suggests that the identification of antibody in oral specimens may serve to reflect cervicovaginal mucosal immunity when cervicovaginal specimens cannot be obtained. However, as discussed below, the need to examine potential mucosal mediators of the vaccine response-for example, STD and cervicovaginal semen-still remains important, and any analysis of an oral mucosal response must take into consideration other potential determinants of local immunity, such as periodontitis [33] [34] [35] and smoking [36, 37] .
The present study was limited by several factors. First, the number of specimens was small. Some specimens could not be collected at scheduled study visits, and some of the withinspecimen analyses did not provide enough valid observations to allow exact conditional logistic regression models to be constructed. The study also was limited, in part, by the logistics of following the EU cohort, who at times were arrested, incarcerated, or otherwise lost to follow-up; however, despite this limitation, 82% of the original cohort was seen at the 36-month study visit. Second, bias may have been introduced into those analyses in which the specimen, not the participant, was the unit of analysis. However, we used generalized estimating equations for our final modeling, to account for repeated sampling from participants. Furthermore, when we repeated the analysis, using the participant as the unit of analysis, and examined the vaccine effect at the 18-and 24-month study visits (i.e., the time when antibody response peaked), the results remained the same (data not shown). We did not measure other potential confounders, such as herpes infection [38, 39] , hormonal contraception [40, 41] , and menstrual cycle [42] , that potentially could have influenced the mucosal immune milieu. Given that secretions of both the female and male genital tracts contain considerably more IgG than secretory IgA [43, 44] , it was not unexpected that mucosal gp120-binding IgA was rarely found in cervicovaginal and gingival specimens. We were unable to determine whether the lack of cervicovaginal IgA was due to the dilute nature of our cervicovaginal specimens or to the lack of vaccine effect at the mucosal level. Examination of specimens for neutralizing activity against a locally produced primary HIV strain demonstrated no association with vaccineinduced binding or neutralizing-antibody responses to HIV-1 MN , and, instead,may be a demonstration of naturally acquired neutralizing activity. Anti-HIV cervicovaginal neutralizing activity was found in 23.9% of the specimens tested. Cervicovaginal neutralizing activity was not associated with either immunization or with the presence of cervicovaginal binding antibody. The measured anti-gp120 binding antibodies of the IgA or IgG type may not have neutralizing activity; however, in the dilute specimens collected from the genital tract, the titers may have been insufficient to neutralize virus: given the dilute nature of the CVL specimens, the assay may not have been sensitive enough. We might have expected that there would be more-robust neutralizing activity in the population studied, given that African Americans have demonstrated increased neutralizing activity to gp120 vaccines [45] . The presence of other innate components in the genital mucosa [46 -48] , additional newly described proteins [49] , or a combination of these factors [50] may have been measured by our assay, thereby reducing its specificity. In additional, semen was found in 23.0% of all cervicovaginal specimens and, in the specimens tested, was positively associated with neutralizing activity (data not shown). It is unclear whether this relationship represents contamination by cervicovaginal semen at that point in time or a marker of high-risk behavior and potential acquired immunity via alloimmunization. However, controlling for the presence of cervicovaginal semen in all multivariate regression models did not change the results and did not mitigate the relationship between vaccine status and the presence of neutralizing activity.
The absence of induced neutralizing activity in the present study may be one of the reasons why this bivalent gp120 vaccine was not effective, but the study lacks the power to address this relationship. Expanding mucosal sampling to EU participants at multiple study sites could add power to statistical analyses and make the results increasingly generalizable. Future studies of candidate vaccines should consider systematic measurement of mucosal immune response as one of the criteria for determination of the potential efficacy of either systemic or mucosal immunization strategies.
